News

Frost & Sullivan Acclaims Corden Pharma for Achieving Excellence in Product Differentiation

16. February 2012

Unique Product Mix and Technical Excellence Distinguish Corden Pharma From the Competition

LONDON--(Marketwire - Jan 10, 2012) - Based on its recent analysis of the pharmaceutical contract manufacturing market, Frost & Sullivan recognises Corden Pharma with the 2011 Western Europe Frost & Sullivan Award for Product Differentiation Excellence.

"Corden Pharma offers unparalleled value to pharmaceutical and biotechnology companies by custom manufacturing of complex pharmaceutical materials and drug products," notes Frost & Sullivan Research Analyst Aiswariya Chidambaram. "Leveraging proprietary technologies and flexible production equipment, the company offers its clients an extensive range of high quality products at cost-effective prices."

The company distinguishes itself from other contract manufacturing organisations (CMOs) by virtue of its technical excellence and unique product portfolio. Core competencies within custom manufacturing include APIs and Drug Product, highly potent peptides, amino acid derivatives and building blocks for peptide synthesis, synthetic phospholipids and lipid derivatives, polymers, carbohydrates, and leading innovations in pseudoproline dipeptides, an important tool in augmenting the efficiency of peptide synthesis.

Click this link to read full press release: http://www.marketwire.com/press-release/Frost-Sullivan-Acclaims-Corden-Pharma-Achieving-Excellence-Product-Differentiation-1604729.htm

Click this link to access the 2011 Western Europe Frost & Sullivan Award Report for Product Differentiation Excellence: http://img.en25.com/Web/FrostSullivan/Corden%20Pharma.pdf

back